A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations

(2008) Stuart A. Scott et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Genetic Testing for Warfarin Therapy Initiation

(2008) Lauren M Hynicka et al.   ANNALS OF PHARMACOTHERAPY

CYP4F2 genetic variant alters required warfarin dose

(2008) M. D. Caldwell et al.   BLOOD

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

(2008) G. M. Cooper et al.   BLOOD

To what extent do scans of non-synonymous SNPs complement denser genome-wide association studies?

(2008) David M Evans et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients

(2008) P. A. LENZINI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A robust statistical method for case-control association testing with copy number variation

(2008) Chris Barnes et al.   NATURE GENETICS

Estimating coverage and power for genetic association studies using near-complete variation data

(2008) Tushar R Bhangale et al.   NATURE GENETICS

Warfarin Pharmacogenetics

(2008) Nita A Limdi et al.   PHARMACOTHERAPY